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Abstract
Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of 
fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and 
exposure-response relationships remain undefined. Our objective of this study was to evaluate the 
association between plasma F-ara-A exposure, the systemically circulating moiety of fludarabine, 
and engraftment, acute graft vs host disease (GVHD), treatment-related mortality (TRM) and 
survival after HCT. The preparative regimen consisted of cyclophosphamide 50 mg/kg/day i.v. 
day −6; plus fludarabine 30-40 mg/m2/day i.v. on days −6 to −2 and TBI 200 cGy on day −1. F-
ara-A pharmacokinetics were performed with the first dose of fludarabine in 87 adult patients. 
Median (range) F-ara-A AUC (0-∞) was 5.0 ug*hr/mL (2.0-11.0), clearance 15.3 L/hour 
(6.2-36.6), Cmin 55 ng/mL (17-166), and concentration on dayzero 16.0 ng/mL (0.1-144.1). Despite 
dose reductions, patients with renal insufficiency had higher F-ara-A exposures. There was strong 
association between high plasma concentrations of F-ara-A and increased risk of TRM and 
reduced overall survival. Patients with an AUC(0-∞) greater than 6.5 ug*hr/mL had 4.56 greater 
risk of TRM and significantly lower survival. These data suggest that clinical strategies are needed 
to optimize dosing of fludarabine to prevent overexposure and toxicity in HCT.
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Introduction
Conventional myeloablative HCT is associated with significant treatment-related morbidity 
and mortality, and therefore often limited to younger patients with good clinical status and 
organ function. Nonmyeloablative or reduced-intensity preparative regimens reduce toxicity 
and risk of TRM, allowing more patients to undergo allogeneic HCT that would otherwise 
not be suitable for traditional transplantation.
Fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine monophosphate), a purine analog with 
potent antitumor and immunosuppressive activity, is a common component of conditioning 
regimens prior to allogeneic nonmyeloablative HCT.1-3 Its immunosuppressive properties 
promote engraftment, development of mixed chimerism, and graft-vs-leukemia effects, 
however, whether fludarabine exposure levels influence engraftment, GVHD, or TRM 
remains unclear.4-6 Fludarabine phosphate is a prodrug that undergoes rapid 
dephosphorylation to the systemically circulating compound, F-ara-A. F-ara-A is then 
phosphorylated intracellularly by several kinases to the active 9-beta-D-arabinofuranosyl-2-
fluoroadenine triphosphate, which is ultimately responsible for inhibition of DNA synthesis 
and RNA production, ultimately resulting in apoptosis.2-3, 7
The pharmacokinetics of fludarabine have been studied extensively in several diseases states 
but limited data exists in HCT.8-18 Fludarabine pharmacokinetics in nonmyeloablative HCT 
was evaluated when combined with busulfan at doses of 30 mg/m2 given daily over 4 days.
19-20 In these reports, sample sizes were limited and the relationship between F-ara-A 
pharmacokinetics and clinical outcomes such as engraftment and toxicity were not 
evaluated.19-20 Therefore, the goal of our study was to evaluate the relationship between 
fludarabine pharmacokinetics, and engraftment, acute GVHD, TRM and survival.
Methods
Patients
This was a single center, pharmacokinetic-pharmacodynamic study of fludarabine in 87 
patients who underwent allogeneic nonmyeloablative HCT. Patients were eligible to 
participate if they met protocol eligibility criteria for transplantation and were to undergo a 
related or unrelated nonmyeloablative allogeneic HCT containing fludarabine, 
cyclophosphamide and TBI along with cyclosporine and mycophenolate mofetil (MMF) for 
posttransplant immunosuppression. This study was approved by the Institutional Review 
Board and the Cancer Protocol Review Committee. All patients provided written informed 
consent.
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Preparative Regimen and Immunosuppression
The preparative regimen consisted of cyclophosphamide 50mg/kg/day i.v. day −6 (total dose 
50mg/kg); fludarabine 40mg/m2/day i.v. on days −6 to −2 (total dose 200mg/m2); and TBI 
200cGy single fraction on day −1 (total dose 200cGy). Fludarabine was dose-reduced to 
30-35mg/m2/day in 9 patients with pre-existing mild to moderate renal impairment at the 
discretion of the clinical team. Patients without intensive chemotherapy in the prior 6 
months received equine antithymocyte globulin 15mg/kg i.v. every 12 hours for 3 days (total 
dose 90 mg/kg), with methylprednisolone 1mg/kg i.v. every 12 hours.
Intravenous MMF and cyclosporine was started on day -3 and converted to oral as tolerated. 
Cyclosporine doses were adjusted to maintain whole blood troughs of 200-400ng/ml.
Fludarabine Pharmacokinetics
F-ara-A pharmacokinetic sampling was prospectively performed with the first dose of 
fludarabine. Fludarabine was administered intravenously over one hour at a constant rate 
and samples were obtained at times 0, 1.6 (100min), 2, 3, 4, 6, 8, 12, and 24 hours after start 
of infusion. On day of transplant a sample was obtained prior to stem cell infusion. Five mL 
of blood was collected at each sampling time and placed in a heparinized green-top tube for 
F-ara-A analysis. All samples, within 60 minutes of collection, were centrifuged at 3400 
rpm for 10 minutes at 4 degrees C, and the plasma removed and stored at -80 degrees C until 
analysis. Plasma serum creatinine (SCr) was obtained on day of pharmacokinetics and 
creatinine clearance (CrCl) estimated by the Cockcroft and Gault equation using ideal body 
weight.21
Bioanalysis
Detection and quantification of plasma F-ara-A was performed with HPLC-UV at 267nm 
(Agilent Technologies, Wilmington, DE). The chromatographic separation was performed 
with a Phenomenex Polar-RP, 4.6 × 250mm, reversed phase column with a 4-micron 
particle size (Phenomenex, Torrance, CA). The mobile phase consisted 50 mM sodium 
phosphate and acetonitrile (90%, 10% v/v) at a pH of 1.6., with a flow-gradient of 0.75 
ml/min for 0-8 min, 1.2 ml/min for 9-22 min and 0.75 ml/min for 0.5 min. Total run time 
was 23 minutes. Following the addition of internal standard (20 ng of 5, 6 
dimethylbenzimidazole) plasma samples (0.75 ml) were extracted using a 3cc Waters Oasis 
MAX solid phase extraction cartridge. The plasma samples were pretreated with 0.8 ml of 
4% phosphoric acid and loaded on to the conditioned SPE cartridge and rinsed with 2 ml of 
4% NH4OH. The final elution was performed with 2 ml of 4% NH4OH in methanol. The 
eluant was dried with a stream of nitrogen at 37 degrees C and reconstituted with 50 ul of 
mobile phase. F-ara-A standard and the 5, 6 dimethylbenzimidazole were obtained from 
Sigma-Aldrich (Milwaukee, WI). The assay was linear in the range of 10-3000 ng/mL. 
Assay accuracy, intraday and interday variability were 93.5-100.1%, 1.6-3.6% and 
1.3-3.3%, respectively.
Pharmacokinetic Analysis
For each patient, F-ara-A plasma concentration-time data was analyzed using 
noncompartmental methods (WinNonLin Professional 5.2). Area-under-the-curve AUC(0-∞) 
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was estimated by the log/linear trapezoidal method as AUC (0-t*) + C(t*)/Ke where C(t*) 
was the last concentration and Ke is the terminal first order elimination rate constant. Ke 
was calculated from the slope of the log-linear portion of the plasma-concentration time 
curve using linear regression analysis. The terminal half-life was 0.693/Ke. Clearance was 
determined by dose/AUC(0-∞). Volume of distribution was estimated from terminal phase of 
the time-concentration data. Cmax was as the largest observed concentration. Cmin(trough) 
was the 24 post dose concentration.
Statistical Analysis
The primary objective of this study was to determine the relationship between F-ara-A 
systemic exposure and neutrophil engraftment. Secondary objectives were to evaluate the 
relationship between F-ara-A exposure and incidence of acute GVHD, TRM, and overall 
survival. Neutrophil engraftment, acute GVHD, TRM, and survival data were collected 
through the transplant database. GVHD was staged and graded according to the standard 
GVHD criteria based on clinical and pathological criteria.22-23 Day of neutrophil 
engraftment was defined as the first of 3 consecutive measures of an absolute neutrophil 
count (ANC) >500 cells/uL in association with partial or complete chimerism by day 42 
after transplantation. Graft failure was defined as survival without an ANC >500 cells/uL at 
day 42 or autologous reconstitution. TRM was death without disease progression or relapse. 
For the survival analysis, death due to any cause was considered an event. Pharmacokinetic 
data was summarized by descriptive statistics. Normal renal function was defined as a CrCl 
>70ml/min. Renal impairment was defined as CrCl< 70ml/min.24
Probabilities and 95% confidence intervals (CI) of acute GVHD and TRM were calculated 
using the cumulative incidence function while neutrophil engraftment and overall survival 
were calculated using the Kaplan-Meier method. Recursive partitioning regression analysis 
was used to determine optimal cutpoints for F-ara-A pharmacokinetic parameters 
(AUC(0-∞), Cmin, clearance, and Dayzero) towards clinical endpoint. Univariate analysis was 
performed evaluating each pharmacokinetic parameter towards neutrophil engraftment, 
TRM at 30 days, 100 days, 6 and 12 months, and overall survival at 6 and 12 months, and 
time to acute GVHD to day 100. Univariate analysis was also performed to evaluate clinical 
factors towards engraftment, TRM, overall survival and acute GVHD.
Cox proportional hazards regression was used to model independent predictors of TRM at 6 
months posttransplantation and included the following: F-ara-A AUC(0-∞), age, use of ATG 
in preparative regimen, recipient CMV status, donor source, comorbidity score25-26, CrCl, 
and acute GVHD grades II-IV.
Results
Patient characteristics are described in Table 1. A total of 87 adult patients had fludarabine 
pharmacokinetic sampling performed. Nine patients received dose reductions of fludarabine 
due to pre-existing renal impairment [30mg/m2/day (n=1), 32mg/m2/day (n=5) and 
35mg/m2/day (n=3)].
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F-ara-A Pharmacokinetics
F-ara-A pharmacokinetics parameters are shown in Table 2. The concentration-time profiles 
for patients receiving the standard dose of fludarabine (40mg/m2) and modified doses of 
fludarabine (30-35mg/m2) are shown in Figure 1. F-ara-A exposure was variable with up to 
a 5.7 fold difference in AUC(0-∞) among patients receiving the standard fludarabine dose of 
40mg/m2/day. Individuals with preexisting mild to moderate renal impairment, despite dose 
reductions of 20-25%, had higher F-ara-A exposures including AUC(0-∞) and trough 
concentrations (Table 2). F-ara-A clearance was reduced by ∼25% in patients with 
decreased renal function. F-ara-A was detectable on day of transplant in all patients. F-ara-A 
dose adjusted AUC(0-∞) was poorly correlated with CrCl (r2=0.22, p< 0.01) and SCr 
(r2=0.02, p=0.18).
Relationship between F-ara-A Exposure and Clinical Outcomes
Engraftment of Donor Cells—Primary neutrophil recovery occurred in 86% of patients 
at a median (range) of 11 days (1-38) following HCT. Graft failure occurred in 14 (16%) 
patients. In univariate analysis, no F-ara-A pharmacokinetic parameters were associated 
with engraftment.
Acute Graft vs Host Disease—Cumulative incidences of grades II-IV and III-IV acute 
GVHD at day 100 were 50% and 17%, respectively. In univariate analysis, patients with an 
F-ara-A AUC(0-∞) >6.5ug*hr/mL had a significantly lower incidence of acute GVHD 
grades II-IV (14%) compared to those ≤6.5ug*hr/mL (52%), p=0.04. No other F-ara-A 
pharmacokinetic parameters were associated with development of grades II-IV or III-IV 
acute GVHD.
Treatment-Related Mortality—The incidence of TRM at 6 months was 21% (95% CI, 
12-29%), occurring at a median of 1.5 months (range, 0.2-6.1) posttransplant (Figure 2, 
panel A). A total of 18 treatment-related deaths occurred with multi-organ failure (n=8) the 
most common cause. Pulmonary and/or cardiac involvement was present in the majority of 
multi-organ failure deaths. The other causes of TRM included encephalopathy (n=3), 
infection (n=3), bleeding/thrombosis (n=3), and acute GVHD (n=1). In univariate analysis, 
patients with F-ara-A AUC(0-∞) >6.5ug*hr/mL had significantly higher cumulative 
incidence of TRM at 6 months (50%) compared to patients with F-ara-A AUC(0-∞) 
≤6.5ug*hr/mL (15%), p<0.01 (Figure 2, panel B). The cause of death in the 7 patients with 
TRM and F-ara-A AUC(0-∞) >6.5ug*hr/mL included multi-organ failure (n=4), 
encephalopathy (n=1), infection (n=1) and bleeding/thrombosis (n=1). TRM at 6 months 
was also significantly higher in patients with F-ara-A clearance ≤12.5L/h when compared to 
patients with an F-ara-A clearance >12.5L/h (45% vs 12%, p<0.01). F-ara-A Cmin>80ng/mL 
was associated with higher cumulative incidence of TRM at 6 months vs F-ara-A Cmin 
≤80ng/mL (64% vs 15%, p<0.01). F-ara-A concentrations on day of transplant ≤30ng/mL 
were also associated with reduced TRM (12%) compared to patients with F-ara-A 
>30ng/mL (53%), p<0.01. Of the 87 patients, 14 patients (16.1%) had F-ara-A AUC(0-∞) 
>6.5ug*hr/mL, 65 patients (74.7%) had troughs >80ng/mL, and 12 patients (10.44%) had an 
F-ara-A clearance <12.5L/h. Seventeen (14%) had F-ara-A concentrations ≥30ng/mL on the 
day of stem cell infusion. F-ara-A pharmacokinetic parameters were also significant 
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(p<0.01) towards TRM at 30 days, 100 days and 12 months (data not shown). In univariate 
analysis other clinical factors associated with higher risk of TRM at 6 months were ATG in 
the preparative regimen (30% vs 11%, p=0.02) and CrCl <70ml/min compared to 
≥70ml/min (22% vs 2%, p<0.01).
The Cox regression analysis for F-ara-A AUC(0-∞) is given in Table 3. At 6 months 
following transplantation, the only independent predictor of TRM was F-ara-A AUC(0-∞). 
Patients with an F-ara-A AUC(0-∞) >6.5ug*hr/mL had a 4.56 greater risk of TRM than 
individuals with an AUC(0-∞) ≤6.5ug*hr/mL (p=0.02).
Overall Survival—Six month overall survival was (71%, 95% CI: 60-80%) with 47 
patients alive at a median of 12 months (range, 0.2-29.5) (Figure 3, panel A). The most 
frequent causes of death were disease relapse or progression (n=7), multi-organ failure 
(n=8), encephalopathy (n=3), infection (n=3), bleeding/thrombosis (n=3), and acute GVHD 
(n=1). In univariate analysis, patients with F-ara-A AUC(0-∞) >6.5ug*hr/mL had 
significantly lower overall survival (36%) at 6 months compared to patients with F-ara-A 
AUC(0-∞) ≤6.5ug*hr/mL (78%), p<0.01 (Figure 3, panel B). Similarly, overall survival at 6 
months was lower in patients with F-ara-A clearance ≤12.5L/h compared to clearance 
>12.5L/h, 41% vs 81%, p<0.01, respectively. Elevated F-ara-A trough >80ng/mL was 
associated with reduced overall survival 6 months posttransplantation (27% vs 76%), 
p<0.01. On the day of transplant, patients with F-ara-A concentrations >30ng/mL had 
significantly lower overall 6 month survival compared to patients with concentrations 
≤30ng/mL (41 vs 80%), p<0.01. Pharmacokinetic parameters were also significant (p<0.01) 
towards overall survival at 12 month (data not shown).
Discussion
This is the first study to evaluate F-ara-A exposure and its relationship to stem cell 
engraftment, GVHD, TRM, and survival in nonmyeloablative allogeneic HCT. We showed 
that F-ara-A exposure is highly variable with 5.7 fold difference in AUC in patients 
receiving fludarabine at 40mg/m2. Our data also demonstrates that higher F-ara-A 
concentrations are associated with a greater risk of TRM and decreased survival. Finally, in 
preparative regimens that use 40mg/m2 of fludarabine, dose reductions greater than 20-25% 
should be considered in patients presenting for transplant with renal impairment.
The pharmacokinetic parameters in our study were consistent to those previously described 
in HCT patients.19-20 Studies outside the setting of HCT demonstrate F-ara-A clearance 
correlates with CrCl, with F-ara-A urinary excretion as high as 60% of the total administered 
dose.13 In phase I trials of fludarabine a decline in renal function was associated with a 
decrease in total body clearance and volume of distribution.18 As as result, fludarabine dose 
reductions of 20-25% are recommended by the manufacturer in patients with CrCl< 70 ml/
min.27 In our study, the nine patients with pre-existing mild to moderate renal impairment 
(median CrCl 57.1ml/min), despite receiving a 20-25% dose reduction, had higher plasma 
concentrations, reduced clearance of F-ara-A, and longer half-life compared to patients not 
receiving dose reductions (median CrCl 85.9ml/min). Therefore, dose reductions >20-25% 
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may be required in HCT patients with mild to moderate renal impairment in preparative 
regimens that use fludarabine 40mg/m2.
Our analyses showed a strong relationship between high plasma F-ara-A exposure, TRM 
and overall survival. This is not surprising since higher exposure may result in greater tissue 
damage, and more potent and longer immunosuppression. A high comorbidity score and 
poor renal function may also be associated with greater TRM, however, they had no 
independent effect in the multivariate analyses. Patients also received cyclophosphamide 
and TBI. The metabolism and clearance of cyclophosphamide and its metabolites have been 
shown to be influenced by renal function and increased concentrations are associated 
increased risk of toxicity in HCT.28-29 Given that multiple factors influence TRM, 
accumulation of F-ara-A plasma concentrations may be a surrogate marker of overall 
preparative regimen intensity.
Higher doses of fludarabine (40-100 mg/m2) have been associated with delayed onset severe 
neurotoxicity including progressive multifocal leukoencephalopathy (PML), coma and 
death. Early phase I/II trials conducted in relapsed leukemia estimated an 18% incidence of 
severe fludarabine neurotoxicity at these doses.30-31 In allogeneic HCT the incidence of 
neurotoxicity and risk factors are not well defined. Fludarabine has been suggested as a 
potential risk factor for neurotoxicity following umbilical cord transplantation.32 Patients 
with elevated systemic plasma concentrations of F-ara-A may experience higher drug 
concentrations in the central nervous system. However, several confounding variables must 
be considered. PML resulting from opportunistic infection with JC virus has been reported 
in chronic lymphocytic leukemia (CLL) patients treated with fludarabine.33-36 More 
recently MMF has been associated with cases reports of PML.37 Finally, all patients in this 
study were treated with cyclosporine. Neurotoxicity, including posterior reversible 
leukoencephalopathy, may occur in up to 30% of patients receiving cyclosporine.38 
Irreversible encephalopathy with the use of cyclosporine in pediatric patients have also been 
reported.39
We found no influence of F-ara-A pharmacokinetic measures on neutrophil engraftment. 
However, our engraftment rate was high thereby reducing our ability to detect an effect. 
Studies in relapsed CLL patients comparing chemotherapy responders vs non-responders 
suggest that sufficient F-ara-A plasma concentrations are needed to maintain a minimum 
inhibitory F-ara-ATP concentration in tumor cells.12 It is possible that the higher 
fludarabine dose, long terminal half-life, combined with the 5 day dosing regimen leads to 
sufficient intracellular F-ara-ATP needed for engraftment. Interestingly, detectable plasma 
F-ara-A was still present on day of transplant in all patients. It is possible that patients 
receiving lower doses of fludarabine (25-30 mg/m2) may not exceed these thresholds. Future 
studies in HCT should incorporate the evaluation of intracellular F-ara-ATP concentrations 
and the potential role of genetic polymorphisms involved in fludarabine pathway including 
cellular transporters, kinases and targets.40-42 Engraftment is a complex process and is 
influenced by several factors including cell dose, donor source, and MMF exposure and 
substantially larger sample sizes will be required to evaluate both genetic and non-genetic 
effects.43
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We found a strong association between higher plasma concentrations of fludarabine and 
increased risk of TRM and reduced overall survival following nonmyeloablative HCT. 
Whether these relationships hold true for other preparative regimens, especially those 
containing lower doses of fludarabine have yet to be established. Renal insufficiency led to 
higher concentrations of fludarabine and dose reductions are warranted to avoid excessive 
systemic exposure. Future studies are needed to further define the minimal level of F-ara-A 
exposure required for stem cell engraftment so that toxicity is minimized.
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Figure 1. F-ara-A Time vs Concentration Profile with first dose of fludarabine1
1data are mean (standard deviation), 2patients receiving standard doses of fludarabine with 
CrCl median (range) of 85.9ml/min (49.5-153.2), 3patients receiving dose modifications of 
fludarabine based on pre-existing mild to moderate renal insufficiency with CrCl median 
(range) of 57.1ml/min (50.5-65.1).
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Figure 2. Cumulative incidence of TRM for patients 6 months after nonmyeloablative HCT
(A) Overall TRM. (B) TRM for patient with F-ara-A AUC(0-∞) ≤6.5ug*hr/mL compared to 
patients with AUC(0-∞) >6.5ug*hr/mL.
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Figure 3. Cumulative proportion of overall survival for patients 6 months after 
nonmyeloablative HCT
(A) Overall survival. (B) Overall survival for patient with F-ara-A AUC(0-∞) ≤6.5ug*hr/mL 
compared to patients with AUC(0-∞) >6.5ug*hr/mL.
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Table 1
Patient Demographics
Median (range) / N (%)
N 87
Age (years) 55(20-69)
Fludarabine dose (mg/m2) 40(30-40)
Weight (kg) 82.6(41.5-139.5)
Male 56 (64%)
Female 31(36%)
Serum creatinine (mg/dL) 1 0.9(0.4-1.5)
Creatinine clearance (mL/min) 1 82.1(49.5-153.2)
Recipient CMV positive 53(61%)
Comorbidity Score 2
 0 9 (10%)
 1-2 32 (37%)
 ≥3 46 (53%)
Disease
 Acute lymphoblastic leukemia 6(7%)
 Acute myelogenous leukemia 26(30%)
 Chronic myeloid leukemia 1(1%)
 Other leukemia 6(7%)
 Myelodysplastic syndrome 14(16%)
 Non-Hodgkin's lymphoma 17(20%)
 Hodgkin's lymphoma 8(9%)
 Other 9(10%)
Graft Source
 Bone marrow 2(2%)
 Peripheral blood stem cell 21(24%
 Cord Blood 64(74%)
   1 umbilical cord 3(5%)
   2 umbilical cords 61(95%)
Donor
 HLA Matched-related 22(25%)
 Unrelated 65(75%)
Disease Risk3
 Standard risk 28(32%)
 High risk 59(68%)
ATG in the conditioning regimen 40(46%)
1
obtained on day of pharmacokinetic sampling,
2Sorror et al (ref 25),
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3Standard risk is defined as acute leukemia in first or second remission and CML in chronic phase, all other malignancies were classified as high 
risk.
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Table 2
F-ara-A pharmacokinetic parameters with first dose of fludarabine1
Standard Dose Dose-Reduced
N 78 9
Fludarabine dose 40mg/m2 30-35mg/m2
Creatinine Clearance, mL/min 85.9(49.5-153.2) 57.1(50.5-65.1)
Cmax, ng/mL 958 (384-2046) 798 (694-1073)
Cmin trough, ng/mL 52 (17-166) 69 (39-93)
AUC(0-∞), ug*hr/mL 4.9 (2.0-11.5) 5.5 (4.3-7.0)
Volume of distribution, L/kg 1.95 (0.89-4.78) 1.72 (1.40-2.51)
Clearance, L/hr 16.0 (6.2-36.6) 11.5 (6.9-15.2)
Half-life, hours 8.53 (3.75-22.18) 10.32 (7.81-14.48)
Dayzero2, ng/mL 15.0 (0.1-144.1) 19.0 (4.0-63.6)
1data are median (range),
2
single concentration obtained on day of transplant
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Table 3
Multiple regression analysis of TRM at 6 months following nonmyeloablative HCT
Factor Relative Risk of TRM (95% CI) P-value
F-ara-A AUC(0-∞) .02
 ≤ 6.5 ug hr/mL* 1.00
 > 6.5 ug hr/mL 4.56 (1.22-17.14)
Age (yrs) .89
 < 55* 1.00
 ≥ 55 0.92 (0.26-3.20)
ATG in conditioning regimen .09
 Yes* 1.00
 No 0.36 (0.11-1.19)
Recipient CMV status .93
 Negative* 1.00
 Positive 0.94 (0.27-3.34)
Donor Source .97
 Matched-related* 1.00
Unrelated 1.03 (0.31-3.40)
Comorbidity Score .18
 0* 1.00
 1-2 0.22 (0.04-1.25)
 ≥3 0.60 (0.12-2.98)
Creatinine clearance .41
 ≥ 70 ml/min* 1.00
 < 70 ml/min 1.63 (0.52-5.13)
aGVHD grades III-IV .15
 No* 1.00
 Yes 2.91 (0.67-12.60)
*
reference group
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